Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Accellacare Salisbury

Neither a doctor nor a teaching hospital

Research payments

$168,732

29 payments

Through program year 2025, Accellacare Salisbury is reported as receiving $168,732 in research payments, across 29 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $21,262 12
2023 Research $1,649 5
2022 Research $15,641 10
2021 Research $130,180 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. OraSure Technologies Inc. $145,430 4 payments
  2. Novartis Pharmaceuticals Corporation $16,645 1 payment
  3. Pfizer Inc. $6,657 24 payments
Studies the money was for Research payments · program years 2021–2025
  1. InteliSwab COVID-19 Rapid Test Clinical Evaluation Study in Asymptomatic Individuals $145,430 4 payments
  2. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $16,645 1 payment
  3. A Phase 3 Placebocontrolled Doubleblinded Randomized Study to Evaluate the Efficacy Safety and Tolerability of A Clostridioides Difficile Vaccine in Adults 65 Years of Age and Older $4,266 10 payments
  4. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $437 2 payments
  5. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $404 1 payment
  6. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $404 1 payment
  7. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $404 1 payment
  8. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $391 8 payments
  9. A Phase 3 Randomized Doubleblind Placebocontrolled Clinical Study Evaluating the Safety Tolerability Immunogenicity and Efficacy of A Variantadapted Bnt162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age $351 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record